TABLE 3

The association between adiponectin +276 and risk of type 2 diabetes according to PPARγ genotype and obesity

Case subjectsControl subjectsOR (95% CI)P for interaction
PPARγ Pro/Pro
 SNP +276
  G/G269 (52.2)392 (52.6)1.0*
  G/T + T/T246 (47.8)354 (47.5)1.09 (0.86–1.39)*0.14
PPARγ Ala
 SNP +276
  G/G51 (40.8)127 (52.1)1.0*
  G/T + T/T74 (59.2)117 (48.0)1.69 (1.04–2.75)*
BMI <30 kg/m2
 SNP +276
  G/G172 (51.5)372 (51.5)1.0
  G/T + T/T161 (48.4)350 (48.5)1.04 (0.79–1.36)0.10
BMI ≥30 kg/m2
 SNP +276
  G/G143 (48.6)143 (56.1)1.0
  G/T + T/T151 (51.4)112 (43.9)1.46 (1.03–1.08)
  • Data are n (%) unless otherwise indicated. The number of case and control subjects in these analyses was less than the overall study due to missing data on PPARγ genotype or obesity.

  • *

    * Adjusted for age (5-year categories), alcohol consumption (nondrinkers, 0–4.9, 5–10, or ≥10 g/day), physical activity (quintiles of metabolic equivalent hours/week), smoking (never, past, and current smoker of 1–14, 15–24, and ≥25 cigarettes/day), and BMI (<23, 23–24.9, 25–29.9, 30–34.9, and ≥35 kg/m2).

  • Adjusted for age (5-year categories), alcohol consumption (nondrinkers, 0–4.9, 5–10, or ≥10 g/day), physical activity (quintiles of metabolic equivalent hours/week), and smoking (never, past, and current smoker of 1–14, 15–24, and ≥25 cigarettes/day).